A vs ARQT
Agilent Technologies vs Arcutis Biotherapeutics, Inc. — AI-powered side-by-side comparison
A
Agilent Technologies
59
Buy
VS
ARQT
Arcutis Biotherapeutics, Inc.
66
Buy
| Metric | A | ARQT |
|---|
| AI Score |
59
|
66
|
| Price |
$156.25
|
$24.85
|
| P/E Ratio |
30.75×
|
112.23×
|
| ROE |
19.3%
|
-8.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
53.0%
|
91.1%
|
| Debt / Equity |
0.47×
|
0.52×
|
| Dividend Yield |
0.7%
|
0.0%
|
| RSI (14) |
61.3
|
33.0
|
| Beta |
1.229
|
1.526
|
| Expected Upside |
+0.2%
|
+2.6%
|
AI Committee View
Current Innellis committee reasoning for A versus ARQT.
ARQT leads by 7 points.
ARQT scores 66/100 (Buy) versus A at 59/100 (Buy).
A Committee View
67% agreement
6 analysts
The primary driver is price structure making higher highs and higher lows. The main limiting factor is bollinger bandwidth of 17.4% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 20.8% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.4 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Bollinger bandwidth of 17.4% signals elevated volatility — Risk
ARQT Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 15.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 113.9 is expensive by classic value standards — Value
- Price-to-book of 18.8x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical